Titan Company Ltd has been gaining attention on Thursday ahead of its FY25 financial results announcement. On May 8, 2025, Titan share price opened at ₹3,349.90, up from its previous close of ₹3,338.90. At 11:13 AM, the share price of Titan was trading at ₹3,391.60, up by 1.58% on the NSE. As of the same time, the stock price touched its day’s high at ₹3,412.50. The market cap of the company was ₹3,01,225.84 crore.  

Growth Across Segments 

The company reported ~25% year-on-year (YoY) growth for Q4FY25 and around 21% YoY growth for the full financial year. Titan’s consolidated retail network expanded significantly with the addition of 72 new stores in the quarter, taking the total to 3,312 stores across geographies. 

Jewellery Business Shines Despite Price Pressure 

The jewellery segment remained the largest contributor to Titan’s performance, registering around 24% YoY growth in Q4FY25. This growth was largely supported by rising gold prices, with plain gold jewellery sales growing at 27% YoY and gold coin sales jumping 65% YoY.  

However, higher gold prices also led to subdued demand at lower price points. Notably, high-ticket purchases saw double-digit growth, pushing average ticket sizes upward. The studded jewellery segment grew in low double digits, while the solitaire category recorded a turnaround with both buyer and value growth. International expansion continued with Tanishq opening stores in Sharjah, Atlanta, and Seattle. 

Watches Division Maintains Momentum 

Titan’s watches division posted a ~20% YoY growth in Q4. Analog watches led the surge with 18% growth, driven by the Titan, Fastrack, and Sonata brands. All key retail formats, Helios, Titan World, and Fastrack, grew in double digits, with Helios leading, reflecting rising demand for premium products. The division added 41 new stores this quarter, enhancing its physical footprint. 

Eyewear Sees Digital Boost, International Push 

The eyewear segment grew ~18% YoY, with both revenue and buyer base contributing. Titan Eyeplus’ multi-brand model proved successful, especially with international brands. E-commerce gained traction, particularly for sunglasses. Titan Eye+ opened two new stores in the UAE and closed 11 stores (net) in India during the quarter. 

Emerging Businesses Show Mixed Trends 

Among emerging verticals, fragrances recorded 26% YoY growth, while fashion accessories rose by 12%. Taneira, however, witnessed a slight decline of ~4% YoY. CaratLane, Titan’s digital-first jewellery brand, grew 22% YoY and added 17 new stores domestically. 

Also Read: Tata Chemicals Sees Profit Dip in FY25! 

Conclusion 

With performance across segments and continued retail expansion, Titan has set the stage for a positive FY25 close. Investors are now awaiting the audited financial results to be announced on May 8, 2025. 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

Computer Age Management Services Limited (CAMS) has been gaining attention on Thursday. On May 8, 2025, CAMS share price opened at ₹3,645.00, up from its previous close of ₹3,642.70. At 10:35 AM, the share price of CAMS was trading at ₹3,721.20, up by 2.15% on the NSE. As of the same time, the stock price touched its day’s high at ₹3,792.00. The market cap of the company was ₹18,393.84 crore.  

Earlier this week, the company announced its financial results for the quarter and year ended March 31, 2025.  

FY25 Annual Financial Performance 

CAMS delivered annual results for FY25 as well. The company posted a revenue of ₹1,422.48 crore, reflecting a 25.2% growth compared to FY24. Profit Before Tax (PBT) grew to ₹624.43 crore, marking a robust 33.0% increase YoY. The company’s PAT stood at ₹470.19 crore, up by 33.0% YoY, with a PAT margin of 31.9%. Basic EPS for FY25 reached ₹95.41 (annual), indicating strong earnings growth. 

Market Leadership in Mutual Funds 

CAMS continued to dominate the mutual fund sector, with several key achievements. The company retained its market leadership with a ~68% market share by Assets Under Management (AUM), servicing 26 out of 51 Asset Management Companies (AMCs). CAMS’ AUM grew by 24% YoY, aligning with the industry’s growth, driven by strong equity assets growth of 29%. The equity market remained resilient with ₹72,624 crore in equity net inflows for the quarter, maintaining stability despite market volatility. 

Growth in SIPs and Investor Base 

Live Systematic Investment Plans (SIPs) grew by 18% YoY, with a total of 5.7 crore SIPs by Q4 FY25. New SIP registrations saw a 51% growth in FY25 compared to FY24. CAMS’ unique investor base crossed the 4 crore mark in the quarter, growing 26% YoY, faster than the industry average of 22%. 

Also Read: CAMS Reports ₹1,422 Crore Revenue in FY25, PAT Up 33% as Non-MF Business Grows 16%! 

Conclusion 

CAMS’ share price has shown positive momentum, rising by 2.15% to ₹3,721.20 by mid-morning on May 8, 2025. The stock hit a high of ₹3,792.00 during the day. This uptick was followed by the company’s financial performance. 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

 

Niva Bupa Health Insurance Company Limited has announced its financial results for the fourth quarter and the full fiscal year ended March 31, 2025.  

Post the announcement, on May 8, 2025, Niva Bupa share price opened at ₹87.03, up from its previous close of ₹81.03. At 9:58 AM, the share price of Niva Bupa was trading at ₹92.11, up by 13.67% on the NSE. 

Profit Growth and Premium Collection 

For FY25, Niva Bupa reported a Profit After Tax (PAT) of ₹214 crore, a sharp 161% jump from ₹82 crore in FY24. The company stated that this substantial increase underscores its improved operational efficiency and sustained business momentum. 

Gross Written Premium (GWP) also reflected growth. In Q4 FY25, the company recorded a GWP of ₹2,395 crore, up 36% YoY. For the entire fiscal year, GWP stood at ₹7,407 crore, registering a 32% increase from the previous year.  

When adjusted for the new IRDAI premium recognition framework (1/N accounting), Q4 GWP was ₹2,079 crore, up 18%, while FY25 adjusted GWP was ₹6,762 crore, showing a 21% rise over FY24. 

Regulatory Impact and Adaptation 

The IRDAI’s revised framework for premium recognition, effective from October 1, 2024, now requires long-term policy premiums to be recognised on an annual basis using the 1/N formula. Despite this change, Niva Bupa maintained a strong growth trajectory, demonstrating its adaptability and resilience in a dynamic regulatory environment. 

Operational Efficiency and Claims Excellence 

Niva Bupa made notable progress in improving operational metrics. Its Claims Settlement Ratio improved from 91.9% in FY24 to 92.4% in FY25, reflecting its commitment to providing a hassle-free claims experience. The Expense of Management was reduced from 39.3% to 37.4%, showcasing successful cost optimisation through automation and digitization across operations. 

Strengthened Financial Position 

The company’s solvency ratio improved significantly from 2.55 in FY24 to 3.03 in FY25, reinforcing its financial stability and ability to meet long-term obligations. This development aligns with Niva Bupa’s long-term strategic focus on maintaining a healthy financial position. 

Market Share Gains  

Niva Bupa increased its Retail Health Market Share from 9.1% to 9.4% YoY, reinforcing its status as a key player in India’s health insurance market.  

Commenting on the results, Krishnan Ramachandran, MD & CEO, Niva Bupa, said, “We are proud of the strong performance we have delivered this year, both in terms of top-line growth and customer service excellence. This growth is a testament to the trust customers place in us and our ability to deliver consistent value.”  

He further stated, “We continue to invest in building a strong and differentiated brand, digital transformation, and expanding our distribution channels to further strengthen our market presence and deliver superior healthcare protection to millions of Indians. Our focus remains on innovating for the customer, simplifying the claims process, and strengthening our digital backbone to drive further efficiencies and scalability.” 

Also Read: Why 40% of Non-Life Policyholders Struggle with Life Insurance? 

Conclusion 

Backed by fundamentals, technological innovation, and strategic clarity, the company is well-positioned to leverage India’s growing demand for health insurance in the years ahead. 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

Coal India Limited (CIL) has announced its financial results for the fourth quarter and the full fiscal year ended March 31, 2025.  

Post the announcement, on May 8, 2025, Coal India share price opened at ₹390.00, up from its previous close of ₹383.30. At 9:47 AM, the share price of Coal India was trading at ₹388.25, up by 1.29% on the NSE. 

Operational Performance 

In Q4 FY 2024-25, CIL recorded coal excavation of 237.69 million tonnes (MT), slightly lower than the 241.76 MT in the same quarter of the previous year. The company saw a 3% year-on-year increase in overburden (OB) removal, which stood at 576.36 million cubic meters (M.CuM), compared to 558.75 M.CuM in Q4 FY 2023-24.  

For the full year, CIL achieved coal production of 781.05 MT, a 1% growth over the previous year. The company also reported a stable offtake of 763.06 MT in FY 2024-25, a 1% growth from the previous fiscal. 

Financial Performance 

CIL reported a slight dip in revenue for Q4 FY 2024-25, which amounted to ₹37,824.54 crore compared to ₹38,213.48 crore in the same quarter of the previous year.  

However, Profit Before Tax (PBT) showed an 11% growth, rising to ₹12,873.19 crore, compared to ₹11,581.57 crore in Q4 FY 2023-24. Profit After Tax (PAT) for Q4 stood at ₹9,592.53 crore, reflecting a 12% increase from ₹8,530.39 crore in the same period last year.  

For FY 2024-25, CIL posted revenue of ₹1,43,368.92 crore, slightly down from ₹1,44,762.42 crore in the previous fiscal year. PBT and PAT for the year were ₹46,966.19 crore and ₹35,302.10 crore, respectively, showing a slight decline year-on-year. 

Capital Expenditure and Government Contribution 

CIL’s capital expenditure (CAPEX) for FY 2024-25 was ₹19,410.02 crore, down from ₹23,475.41 crore in the previous year. Despite this, the company contributed ₹60,959.52 crore to the government exchequer, slightly higher than the ₹60,197.80 crore contributed in FY 2023-24, reflecting its ongoing contribution to the national economy. 

Coal India Dividend Announcement 

The Board of Directors of CIL has recommended a final dividend of ₹5.15 per share for FY 2024-25, subject to shareholder approval at the Annual General Meeting (AGM). Combined with the interim dividend of ₹21.35 per share, the total dividend for the fiscal year will amount to ₹26.50 per share, a 10% increase from the previous fiscal year’s total dividend of ₹25.50 per share. 

Also Read: Cabinet Approves Revised SHAKTI Policy Governing Coal Allocation to the Power Sector! 

Conclusion 

Coal India Limited’s performance in FY 2024-25, coupled with consistent dividends and significant contributions to the government, highlights the company’s position in India’s coal sector. 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

 

Tata Chemicals Limited has announced its financial results for the fourth quarter and full year ended March 31, 2025. 

Post the announcement, on May 8, 2025, Tata Chemicals share price opened at ₹821.00, down from its previous close of ₹826.20. At 9:41 AM, the share price of Tata Chemicals was trading at ₹836.00, up by 1.19% on the NSE. 

Q4 FY25 Performance Affected by Global Headwinds 

In Q4 FY25, Tata Chemicals recorded a consolidated revenue from operations of ₹3,509 crore, marking a 1% year-on-year increase. Despite this marginal growth, the company faced sustained pricing pressure across geographies, which impacted profitability. EBITDA dropped to ₹327 crore from ₹443 crore in the same quarter last year.  

The company also reported a net loss of ₹12 crore (before exceptional items and NCI) compared to a profit of ₹145 crore in Q4 FY24. 

One of the significant factors contributing to the subdued quarterly performance was the cessation of soda ash operations at the Lostock plant in the UK. This led to an exceptional charge of ₹55 crore in Q4 FY25. Additionally, gross debt increased to ₹7,072 crore as of March 31, 2025, primarily due to higher working capital loans in India, the US, and the UK. 

Full-Year FY25 Summary 

For the full financial year, Tata Chemicals reported a consolidated revenue of ₹14,887 crore, slightly lower than ₹15,421 crore in FY24. EBITDA stood at ₹1,953 crore, down from ₹2,847 crore, mainly due to compressed margins amid lower product pricing. 

Despite these challenges, the company posted a Profit After Tax of ₹479 crore (before exceptional items and NCI). Exceptional charges for FY25 totaled ₹125 crore, related to closure expenses of the Lostock plant.  

On the positive side, Tata Chemicals successfully commissioned significant capacity expansions, including a 230kT soda ash and 140kT bicarb facility in India and a 70kT pharma-grade salt facility in the UK. 

Management Commentary 

Commenting on the results, R. Mukundan, Managing Director & CEO, Tata Chemicals Limited, said, “Market conditions remain challenging even as India continues to grow while China, US and Western Europe are witnessing slight declines due to reduced demand for flat and container glass. In other regions, Asia (excluding China and India) and Americas (excluding USA) demand is robust, while slight decline is observed in demand of Africa. Though demand – supply balance softens, tariff uncertainties will continue to weigh on market, medium- and long-term outlook remains positive driven by sustainability trends.”  

 He further added, “The company’s overall performance is lower compared to Q4FY24, mainly due to pricing pressure in all geographies. During the FY25, Company commissioned 230kT Soda Ash and 140kT Bicarb capacity in Mithapur, India. In a move to focus UK operations to high-grade value-added products 70kT pharma grade salt capacity was commissioned in Middlewich, UK.”  

“Our endeavor is to Excel in operations through innovation, digitization and customer delight. We continue our journey to Embed sustainability guided by Project Aalingana. Our focus to Expand the core while being calibrated will also include broadening the portfolio,” said R. Mukundan.  

Also Read: Tata Motors Announces Shareholder Approval for Demerger!

Conclusion 

While FY25 posed challenges for Tata Chemicals due to global pricing pressure and restructuring costs, the company remains focused on capacity expansion and long-term growth. Strategic investments in India and the UK signal confidence in future demand recovery and operational efficiency. 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

Lupin Limited, a leading global pharmaceutical company, has announced the launch of Eslicarbazepine Acetate Tablets in the U.S. following approval from the U.S. Food and Drug Administration (FDA).  

The launch includes 200 mg, 400 mg, 600 mg, and 800 mg strengths. These tablets are the generic equivalent of Aptiom®, originally developed by Sumitomo Pharma America, Inc. 

Generic Exclusivity and Market Potential 

Lupin is one of the first companies to file an Abbreviated New Drug Application (ANDA) for this product and has secured 180 days of shared generic exclusivity. This strategic positioning allows Lupin early entry into a lucrative market. According to IQVIA MAT data for March 2025, the reference drug Aptiom® generated estimated annual sales of USD 395 million in the U.S. 

Eslicarbazepine Acetate Tablets are indicated for the treatment of partial-onset seizures in patients aged 4 years and older. The launch enhances Lupin’s neurology portfolio and supports improved access to epilepsy treatment options. 

Lupin Updates Timeline for Slump Sale Transactions 

Meanwhile, Lupin has revised the timeline for two key slump sale transactions previously disclosed to the exchanges. The Business Transfer Agreement (BTA) for the transfer of its API R&D Division to Lupin Manufacturing Solutions Limited (LMSL) is now expected to be executed by June 30, 2025, instead of the earlier communicated April 30, 2025.  

Similarly, the BTA for transferring its Over-the-Counter Consumer Healthcare Business to LupinLife Consumer Healthcare Limited (LCHL) is also expected to be signed by June 30, 2025, or on a mutually agreed later date. 

Lupin Share Price Performance 

On May 7, 2025, Lupin share price opened at ₹2,025.10 and closed at ₹2,073.00, up by 1.17%. The stock price touched its day’s high at ₹2,074.90. 

Also Read: Lupin Posted About the US Launch of gTolvaptan With $200 Million FY26 Potential! 

Conclusion 

With this launch, Lupin reinforces its commitment to delivering high-quality, affordable generics in the U.S. market while expanding its presence in the central nervous system (CNS) therapeutic area. The Board of Directors of the company will meet on Wednesday, May 14, 2025, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, and to recommend a dividend, if any. 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

Bajaj Finance Limited’s Board of Directors has declared and approved a special interim dividend of ₹12 per equity share at a face value of ₹2 each for the financial year ended March 31, 2025.  

On May 7, 2025, Bajaj Finance share price (NSE: BAJFINANCE) opened at ₹8,750.00 and closed at ₹8,977.00, up by 2.04%. The stock price touched its day’s high at ₹8,997.50.  

Bajaj Finance Special Dividend Record Date 

The Board of Directors has declared a Special (Interim) Dividend of ₹12 per equity share (600% of the face value of ₹2) for the financial year ending March 31, 2025. This dividend will be credited or dispatched on or around May 26, 2025. 

The Special Dividend has been announced following an exceptional gain from the sale of the company’s investment in Bajaj Housing Finance Limited (BHFL), linked to its IPO listing in September 2024. 

The record date to determine eligible shareholders for this dividend has been set as May 9, 2025. 

Q4 FY 2025 Financial Highlights 

In Q4 FY25, the company recorded growth across key metrics. The number of new loans booked rose by 36% year-on-year, reaching 10.10 million compared to 7.87 million in Q4 FY24. Its customer franchise crossed the 100 million milestone, standing at 101.82 million as of March 31, 2025, a 22% increase from 83.64 million in the previous year. During Q4 FY25 alone, the customer base expanded by 4.70 million. 

Assets under management (AUM) witnessed a 26% jump, rising to ₹4,16,661 crore from ₹3,30,615 crore as of March 2024, with an increase of ₹18,618 crore during Q4 FY25. The company’s net interest income rose 22% to ₹9,807 crore, while profit after tax grew 19% year-on-year to ₹4,546 crore. 

Also Read: Bajaj Finance Declared Bonus Shares, 1:1 Stock Split, and Record ₹56 Dividend! 

About Bajaj Finance Ltd 

Bajaj Finance primarily operates in the lending space, offering a diversified portfolio that caters to retail, SME, and commercial clients. The company maintains a strong footprint across both urban and rural regions of India. 

Conclusion 

Bajaj Finance’s special dividend reflects its financial position and gains from BHFL’s IPO. Shareholders as of May 9, 2025, will be eligible. Additionally, the Board has approved a stock split (1:2) and a generous 4:1 bonus share issue. 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

Government stocks, or public sector stocks, are shares of companies where the Indian government holds a major stake. These companies operate across sectors like banking, energy, infrastructure, and defence. In this article, find the best government stocks in May 2025, based on the 5-yr CAGR and other parameters like net profit margin and return on investment.  

Best Government Stocks in India May 2025 – Based on 5yr CAGR 

Note: The best government stocks list provided here is as of May 7, 2025. The stocks selected are of positive 1-yr returns and sorted based on their 5-yr CAGR. 

Overview of the Best Government Stocks in May 2025 

1. Rail Vikas Nigam Ltd 

Rail Vikas Nigam Ltd (RVNL) takes up a range of rail infrastructure projects entrusted by the Ministry of Railways (MoR). For the nine months ended FY 2025, the company reported a total income of ₹14,308.89 crore, down from ₹16,080.49 crore in the same period of FY 2024. Its net profit also declined to ₹822.41 crore from ₹1,096.08 crore year-on-year. 

Key metrics: 

• Return on Equity (ROE): 19.69% 

• Return on Capital Employed (ROCE): 17.44% 

2. Hindustan Aeronautics Ltd (HAL) 

Hindustan Aeronautics Ltd is involved in the manufacturing of aircraft and helicopters and repairs and maintains them. The company is a Navaratna Status Public Sector Undertaking (PSU) under the Ministry of Defence. In 9M ended FY 2025, the company’s total income was ₹19,19,126 lakh, a rise from ₹16,95,162 lakh during the same period in FY 2024. The net profit was ₹4,38,742 lakh in 9M ended FY 2025, a rise from ₹3,31,227 lakh YoY.  

Key metrics: 

• ROE: 28.91% 

• ROCE: 24.58% 

3. Bharat Electronics Ltd (BEL) 

BEL is a Navratna PSU under the Ministry of Defence, Government of India. The company provides advanced electronic products for the Indian Army. BEL has achieved a total income of ₹15,16,688 lakh, marking a growth in the 9M ended FY 25, compared to ₹12,14,887 lakh during the same period last year. The PAT for the 9M of FY 25 stood at ₹3,19,566 lakh, reflecting a growth from ₹2,18,857 lakh recorded in the corresponding period of the previous year. 

Key metrics: 

• ROCE: 30.17% 

• ROE: 26.37%

4. Bharat Dynamics Ltd (BDL) 

Bharat Dynamics Ltd is into the manufacturing base for guided missile systems and allied equipment for the Indian Armed Forces. In 9M ended FY 2025, the company’s total income was ₹1,81,890.83 lakh, an increase from ₹1,78,849.59 lakh during the same period in FY 2024. The net profit was ₹27,687.33 lakh, a decline from ₹32,394.42 lakh during the same period in FY 2024. 

Key metrics: 

• ROCE: 11.34% 

• ROE: 17.89% 

5. Cochin Shipyard Ltd 

Established in 1972, Cochin Shipyard Limited (CSL) is a prominent company engaged in building a wide range of vessels and carrying out repairs, refits, periodic upgrades, and life extension of ships. CSL is a Schedule A Miniratna enterprise operating under the Ministry of Ports, Shipping, and Waterways. In 9M ended FY 2025, the company’s total income was ₹3,294,23.66 lakh, a rise from ₹2,774,46.83 lakh during the same period in FY 2024. The net profit was ₹54,014.70 lakh, an increase from ₹52,455.74 lakh during the same period in FY 2024. 

Key metrics: 

• ROCE: 20.24% 

• ROE: 16.61% 

Best PSU Stocks in India in May 2025 – Based on Net Profit Margin 

Note: The best government stocks list provided here is as of May 7, 2025. The stocks are sorted based on their net profit margin. 

Best PSU Stocks in India in May 2025 – Based on Return on Investment 

Note: The best government stocks list provided here is as of May 7, 2025. The stocks are sorted based on their return on investment. 

Pros of Investing in Government Stocks 

• Stability: Government backing can offer financial stability, consistent operations, and preferential treatment in policymaking. 

• Long-Term Growth Potential: Infrastructure, energy, and defence PSUs often benefit from government policies and long-term projects. 

• Monopoly or Market Dominance: Some government-owned companies hold dominant positions in their industries. 

Cons of Investing in Government Stocks 

• Government Influence: Policies, disinvestment, or political decisions may impact business operations and stock performance. 

• Limited Innovation: Compared to private players, PSUs often show slower innovation, expansion, and return on equity due to bureaucratic processes. 

Also Read: Best Long-Term Stocks in May 2025 – 5yr CAGR Basis!  

Conclusion 

Apart from the government stocks given above, there are several other companies owned by state and central governments. Before investing, it is important to analyse the company’s business, financials, and growth prospects. Always assess your investment objective and risk tolerance before making a decision. 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.